Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
286 participants
INTERVENTIONAL
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perennial Allergic Rhinitis In Pediatric Subjects
NCT00257595
Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis
NCT00490204
Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics
NCT00257582
Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis
NCT00639587
Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis
NCT01539304
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetirizine Dry Syrup
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Giving informed consent.
* Children with a positive response to specific IgE antibody test.
* Children assessed as positive in the nasal eosinophil count.
* Children whose severity score of nasal symptom is 4 or higher.
Exclusion Criteria
* have a history of drug hypersensitivity
* are pregnant, lactating or possibly pregnant female Children
* are sensitive to pollen as a duplicate allergen and whose treatment periods are thought in the pollen dispersion periods
* have vasomotor rhinitis and eosinophilic rhinitis
* have asthma that requires the treatment with corticosteroid
* have inappropriate complication of nasal disorder that may influence on the evaluation of the study drugs
* have complicated with atopic dermatitis or urticaria that requires the treatment with antihistamine preparation
* have started specific desensitization treatment or nonspecific modulation treatment but who have not reached the maintenance level of treatment
* have received surgical treatment for reduction and modulation of nasal mucosa
* redintegration therapy of nasal cavity to improve the degree of nasal airway
* surgical operation to improve rhinorrhea.
3 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
104912
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.